Free Trial

Myriad Genetics (MYGN) Competitors

Myriad Genetics logo
$7.80 -0.04 (-0.51%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$7.67 -0.13 (-1.65%)
As of 10/14/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MYGN vs. FOLD, CLDX, BCRX, MNKD, NVAX, OPK, DVAX, ZBIO, INVA, and GERN

Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Geron (GERN). These companies are all part of the "biotechnology" industry.

Myriad Genetics vs. Its Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, Amicus Therapeutics had 9 more articles in the media than Myriad Genetics. MarketBeat recorded 17 mentions for Amicus Therapeutics and 8 mentions for Myriad Genetics. Amicus Therapeutics' average media sentiment score of 0.99 beat Myriad Genetics' score of 0.77 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amicus Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Myriad Genetics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amicus Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

Amicus Therapeutics presently has a consensus price target of $15.78, indicating a potential upside of 96.24%. Myriad Genetics has a consensus price target of $12.45, indicating a potential upside of 59.67%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Myriad Genetics
2 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

Amicus Therapeutics has a net margin of -6.67% compared to Myriad Genetics' net margin of -47.45%. Amicus Therapeutics' return on equity of -5.07% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amicus Therapeutics-6.67% -5.07% -1.23%
Myriad Genetics -47.45%-5.17%-3.44%

Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$571.16M4.34-$56.11M-$0.12-67.00
Myriad Genetics$832.90M0.87-$127.30M-$4.28-1.82

99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Amicus Therapeutics beats Myriad Genetics on 13 of the 17 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYGN vs. The Competition

MetricMyriad GeneticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$729.47M$3.35B$6.04B$10.50B
Dividend YieldN/A2.30%5.73%4.80%
P/E Ratio-1.8221.9084.6427.24
Price / Sales0.87263.81508.12197.88
Price / Cash7.8546.9537.5761.53
Price / Book1.0110.4312.256.74
Net Income-$127.30M-$52.58M$3.32B$276.59M
7 Day Performance2.09%-1.55%-1.34%-0.47%
1 Month Performance6.70%12.96%8.14%7.47%
1 Year Performance-67.47%15.43%72.27%34.58%

Myriad Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYGN
Myriad Genetics
3.5688 of 5 stars
$7.80
-0.5%
$12.45
+59.7%
-68.9%$729.47M$832.90M-1.822,700News Coverage
Analyst Forecast
FOLD
Amicus Therapeutics
4.5175 of 5 stars
$8.18
-1.4%
$15.78
+92.9%
-22.8%$2.56B$528.29M-68.16480
CLDX
Celldex Therapeutics
2.1386 of 5 stars
$27.13
+1.3%
$43.78
+61.4%
-12.6%$1.78B$7.02M-9.01150News Coverage
Analyst Forecast
BCRX
BioCryst Pharmaceuticals
4.1886 of 5 stars
$7.04
-2.5%
$16.30
+131.5%
-13.9%$1.52B$450.71M-39.11530Trending News
Gap Down
MNKD
MannKind
3.9382 of 5 stars
$5.10
+4.5%
$10.86
+112.9%
-22.0%$1.50B$285.50M46.37400Analyst Forecast
NVAX
Novavax
4.2464 of 5 stars
$8.62
+3.5%
$12.33
+43.1%
-29.6%$1.35B$682.16M3.781,990News Coverage
OPK
OPKO Health
4.3208 of 5 stars
$1.51
flat
$2.63
+73.8%
+3.4%$1.20B$713.10M-6.042,997
DVAX
Dynavax Technologies
4.5707 of 5 stars
$10.01
+0.5%
$24.33
+143.1%
-6.0%$1.17B$277.25M-21.76350
ZBIO
Zenas BioPharma
2.259 of 5 stars
$26.54
-0.2%
$38.33
+44.4%
N/A$1.12B$5M-7.48N/ANews Coverage
Insider Trade
Analyst Revision
Gap Down
INVA
Innoviva
4.8286 of 5 stars
$16.94
-2.4%
$37.60
+122.0%
-16.2%$1.09B$358.71M54.65100
GERN
Geron
2.4909 of 5 stars
$1.27
-3.1%
$3.79
+198.1%
-70.0%$835.80M$76.99M-9.7770News Coverage

Related Companies and Tools


This page (NASDAQ:MYGN) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners